Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EMBC
EMBC logo

EMBC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Embecta Corp (EMBC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.130
1 Day change
-4.90%
52 Week Range
15.550
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Embecta Corp (EMBC) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has some positive technical indicators, such as a positive MACD and neutral RSI, the lack of significant catalysts, declining financial metrics, and neutral sentiment from hedge funds and insiders suggest a cautious approach. Additionally, analysts have recently lowered their price targets, reflecting a less optimistic outlook. Given the investor's preference for long-term growth, it would be prudent to wait for clearer signs of improvement in financial performance or stronger positive catalysts before considering this stock.

Technical Analysis

The MACD histogram is positive at 0.14 and expanding, indicating bullish momentum. However, RSI_6 at 73.886 is in the neutral zone, suggesting no clear overbought or oversold condition. Moving averages are converging, which indicates a lack of strong directional trend. The stock is trading close to its pivot point (9.113), with resistance at 9.577 and support at 8.649.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
4

Positive Catalysts

  • The MACD is expanding positively, indicating potential bullish momentum. The stock has a 40% chance of gaining 9.61% in the next month based on historical candlestick patterns.

Neutral/Negative Catalysts

  • Revenue dropped by -0.27% YoY in Q1 2026, and gross margin declined by -4.42% YoY. Analysts have lowered price targets recently, reflecting a cautious outlook. No significant news or event-driven catalysts are present. Hedge funds and insiders are neutral, and there is no recent congress trading data.

Financial Performance

In Q1 2026, revenue dropped slightly by -0.27% YoY to $261.2M. Net income and EPS remained flat at $44.1M and $0.74, respectively. Gross margin declined by -4.42% YoY to 60.91%, indicating some pressure on profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Mizuho lowered the price target to $12 from $14 with a Neutral rating, while BTIG lowered the price target to $22 from $25 but maintained a Buy rating. Analysts are cautious, reflecting broader concerns in the medical devices sector.

Wall Street analysts forecast EMBC stock price to rise
Analyst Rating
0
Wall Street analysts forecast EMBC stock price to rise
Buy
Hold
Sell
0
Current: 9.600
sliders
Low
0
Averages
0
High
0
0
Current: 9.600
sliders
Low
0
Averages
0
High
0
Mizuho
Neutral
downgrade
$14 -> $12
AI Analysis
2026-04-13
Reason
Mizuho
Price Target
$14 -> $12
AI Analysis
2026-04-13
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Embecta to $12 from $14 and keeps a Neutral rating on the shares. The firm lowered estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
BTIG
Buy
downgrade
$25 -> $22
2026-04-13
Reason
BTIG
Price Target
$25 -> $22
2026-04-13
downgrade
Buy
Reason
BTIG lowered the firm's price target on Embecta to $22 from $25 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EMBC
Unlock Now

People Also Watch